1 week Ago By ABMN Staff
Norges Bank purchased a new position in shares of Alumis Inc. ( NASDAQ:ALMS – Free Report ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 204,361 shares of the company’s stock, valued at approximately $1,606,000.
A number of other institutional investors and hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in Alumis during the third quarter worth $27,000. China Universal Asset Management Co.
Ltd. acquired a new position in shares of Alumis during the 4th quarter worth $79,000. JPMorgan Chase & Co.
purchased a new stake in shares of Alumis in the 3rd quarter worth about $191,000. Barclays PLC acquired a new stake in Alumis in the 3rd quarter valued at about $197,000. Finally, State Street Corp purchased a new position in Alumis during the 3rd quarter valued at about $866,000.
Analysts Set New Price Targets ALMS has been the topic of several recent research reports. Oppenheimer initiated coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.
00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alumis in a research note on Wednesday, March 26th.
Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Alumis currently has an average rating of “Buy” and a consensus target price of $26.
00. Alumis Stock Performance Shares of NASDAQ ALMS opened at $6.48 on Friday.
Alumis Inc. has a 1 year low of $3.18 and a 1 year high of $13.
53. The firm’s 50 day moving average price is $5.63 and its 200 day moving average price is $8.
06. Insider Transactions at Alumis In related news, CEO Martin Babler purchased 15,650 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average price of $6.
44 per share, with a total value of $100,786.00. Following the completion of the transaction, the chief executive officer now owns 106,454 shares of the company’s stock, valued at approximately $685,563.
76. This trade represents a 17.23 % increase in their position.
The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Alan Colowick purchased 16,104 shares of the firm’s stock in a transaction on Tuesday, April 1st. The stock was bought at an average price of $6.
97 per share, for a total transaction of $112,244.88. Following the acquisition, the director now owns 16,104 shares in the company, valued at $112,244.
88. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here .
About Alumis ( Free Report ) Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. ( NASDAQ:ALMS – Free Report ).
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter ..
